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Abstract
When engagement with a randomized trial is driven by factors that affect the outcome
or when trial engagement directly affects the outcome independent of treatment, the
average treatment effect among trial participants is unlikely to generalize to a target
population. In this paper, we use counterfactual and graphical causal models to ex-
amine under what conditions we can generalize causal inferences from a randomized
trial to the target population of trial-eligible individuals. We offer an interpretation of
generalizability analyses using the notion of a hypothetical intervention to “scale-up”
trial engagement to the target population. We consider the interpretation of general-
izability analyses when trial engagement does or does not directly affect the outcome,
highlight connections with censoring in longitudinal studies, and discuss identification
of the distribution of counterfactual outcomes via g-formula computation and inverse
probability weighting. Last, we show how the methods can be extended to address
time-varying treatments, non-adherence, and censoring.
1 Introduction
Randomized trials are widely regarded as the tool of choice to obtain estimates of average
treatment effects that are, in expectation, unaffected by baseline confounding. The sample
of participants in a trial, however, may not be representative of the target population of
all trial-eligible individuals, including individuals who meet the trial eligibility criteria but
were not invited to participate or those who were invited but chose not to participate. This
situation begs the question of whether the effect estimates based on the sample of trial
participants can be generalized to the target population.
If individuals in the trial were a random sample of the target population, then the effect
estimates from the sample would be directly generalizable to the target population. Unfor-
tunately, that is often not the case. The selection from the target population to the trial
sample is a complex process that may result in a different distribution of effect modifiers [1]
for individuals in the target population compared with those in the trial sample. When
this happens, generalizability requires statistical adjustments and unverifiable assumptions
derived from expert knowledge.
In recent years, the problem of selective participation in randomized trials has inspired
work [2–8] on “generalizability methods” which integrate statistical methods and unverifiable
assumptions. However, most developments of generalizability methods (including ours [8])
have considered simplified settings restricted to time-fixed treatments under complete ad-
herence and have paid little attention to the processes that determine participation in a
randomized trial. Specifically, prior work has not distinguished between (1) the invitation
to participate in the trial and (2) the decision to participate in the trial after receiving the
invitation. A better conceptualization of the selection process is important for two reasons.
First, the mechanisms that determine whether an eligible individual is invited to partic-
ipate in a trial may differ from those that determine whether an invited individual decides
to participate. Therefore, valid generalization from the sample of trial participants to the
target population of all trial-eligible individuals will typically require data about these dif-
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ferent mechanisms. Though understood in other contexts (e.g., [9]), the need to consider
invitation and participation separately has not been considered in the recent literature on
generalizability. A practical implication is that generalizability methods will require data
from non-invited trial-eligible individuals in addition to data from invited individuals who
did and did not participate in the trial.
Second, the invitation to participate in the trial and trial participation itself may have
direct causal effects on the outcome that are not mediated by treatment. For example, being
made aware of the trial’s existence may affect the behavior of both participants and non-
participants (e.g., via Hawthorne effects), and participation may affect components of the
participants’ medical care other than the treatment itself. A practical implication is that
generalizability methods will need to explicitly consider these direct effects.
In this paper, we structurally describe the invitation and participation components of the
selection from the target population of trial-eligible individuals to the sample of randomized
trial participants, formalize generalizability from the trial sample to the target population
as an attempt to emulate a hypothetical intervention to (1) scale-up trial engagement (both
invitation and participation) and (2) assign treatment to the target population. We con-
sider generalizability when trial engagement does and does not directly affect the outcome,
highlight connections with censoring in longitudinal studies, and discuss identification of
the distribution of counterfactual outcomes via g-formula computation and inverse proba-
bility weighting. Lastly, we show how the methods can be extended to address time-varying
treatments, non-adherence, and censoring.
2 Conceptual model
The invitation to participate in a trial is the process that results in certain trial-eligible
individuals becoming aware of the trial, being asked to participate in it, and being asked
to provide informed consent. Participation in a trial is the consent given by some invited
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individuals to be assigned to a treatment and being followed up as in the trial. We use the
term “engagement” as shorthand for the combination of the invitation to participate and for
participation in the trial.
To fix ideas, consider a randomized trial to compare the effect of two types of surgery,
gastric bypass and adjustable gastric band surgery, on weight and quality-of-life after 5 years
(similar to the By-Band trial [10]). The target population of trial-eligible individuals are
adults with a body mass index (BMI) of 40 kg/m2 or more, or BMI of 35 kg/m2 or more
and other co-morbidities that could improve with weight loss, and who are fit for anesthesia
and surgery in the catchment area of 10 hospitals.
Let R be the indicator of invitation to participate in this trial (1 if invited; 0 otherwise),
and S the indicator of trial participation (1 if participating; 0 otherwise). The invitation
to participate R is under (partial) investigator control, in the sense that investigators can
employ outreach strategies to increase trial awareness among eligible individuals, whereas
participation S is almost entirely not under investigator control (except in exceptional cir-
cumstances when the requirement for informed consent is waived) [11].
Let Z be treatment assignment (i.e., 1 for gastric bypass, 0 for adjustable gastric band
surgery), and Y the outcome (i.e., weight or quality-of-life at 5 years). Among individuals
participating in the trial, treatment assignment occurs by randomization, whereas among
non-participants treatment assignment occurs in the form of a recommendation or prescrip-
tion (the treatments that can be assigned to trial participants and non-participants may be
different). Both participants and non-participants in the trial may decide not to adhere to
their assigned treatment or the follow-up plan, but, for now, we limit our consideration to
trials with perfect adherence complete follow-up, so that the assigned treatment is always
the received treatment and there is no drop-out. We revisit non-adherence in Section 7.
The causal directed acyclic graph (DAG) in panel (A) of Figure 1 depicts the causal
structure connecting variables R, S, Z, and Y . The arrow R → S represents that non-
invited individuals cannot participate in the trial. The arrow R → Z represents that invited
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individuals (R = 1) who decline participation (S = 0) may receive a different treatment
recommendation Z. The arrow S → Z represents that the assignment mechanism is different
between trial participants and non-participants. Also, among non-participants, unmeasured
prognostic factors U may also affect the treatment assignment, as represented by the fork Z ←
U → Y . Panel (B) of Figure 1 shows the causal DAG for the subset of trial participants, in
which the following three statements hold: (1) if S = 1, then R = 1, that is, trial participation
implies the invitation to participate; (2) there is no confounding by U of the effect of Z on
Y ; and (3) treatment assignment is not affected by the invitation to participate (no arrow
R → Z).
Figure 1 also includes measured prognostic factors X that may affect the invitation to
participate (X → R), trial participation (X → S), and treatment assignment (X → Z),
if randomization is conditional on covariates for trial participants (S = 1) or if treatment
recommendations vary depending on the characteristics of non-participants (S = 0).
A key feature of Figure 1 is the consideration of possible direct effects of invitation
(R → Y ) and participation (S → Y ) on the outcome that are not through treatment Z [12,13].
That is, we allow for a direct effect of trial engagement on the outcome.
In our example, invitation R can have a direct effect on the outcome Y if the invitation
to participate increases awareness about the adverse effects of obesity, which in turn affects
the reporting of body weight even among non-participants [12] or leads to the adoption of
healthy behaviors (say, daily exercise) that directly affect body weight (not through Z).
Participation S can have a direct effect on the outcome Y if providers are particularly
attentive to trial participants, who in turn are more likely to report improved subjective
outcomes (e.g., quality of life) due solely to the increased attention. Effects due to the
experience of being observed or experimented on are often referred to as Hawthorne effects
[12, 14]. Another way in which participation S can have a direct effect on the outcome Y is
though exposure of the trial participants to concomitant interventions that differ from those
in usual practice and that affect the outcome [12]. In our example, participants are required
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to attend regular clinic visits, during which providers may recommend changes to diet or
exercise habits, and these changes may directly affect the outcome.
In the presence of direct effects of trial engagement, generalizability methods need to be
modified as described in the next section. As we will see, such effects are hard to identify
from studies in which treatment assignment Z is the only randomized intervention [15]. We
will consider settings without direct effects of trial engagement in Section 5.
3 Joint intervention to scale-up trial engagement and
set treatment
Questions about generalizing causal inferences about treatments assessed in trials can be
recast as questions about hypothetical joint interventions to (1) scale-up trial engagement to
the target population and (2) assign treatment. We can use single world intervention graphs
(SWIGs) to represent these joint interventions. In Appendix A, we summarize aspects of
SWIGs that are relevant to our setup; references [16] and [17] provide additional details.
Informally, a SWIG can be thought of as a causal DAG depicting a world where we have
intervened to set the value of one or more variables in accordance with some treatment regime
or strategy. SWIGs [17] are attractive graphical tools because they (1) distinguish between
nodes that are and are not intervened on and (2) depict counterfactual variables, allowing us
to read off independence conditions that involve counterfactuals using d-separation [18, 19].
Starting with the DAG of Figure 1, we construct the SWIG of Figure 2 for a hypothetical
intervention to set R to r = 1, S to s = 1 and Z to z. We split the nodes R, S, and
Z to denote the joint intervention, inducing three counterfactual outcomes [20] (potential
outcomes [21]): the participation status under intervention to invite all members of the
population to the trial, Sr=1; the treatment assignment after intervention to scale-up trial
participation, Zr=1,s=1; and the outcome under joint intervention to scale-up trial engagement
and set treatment to z, Y r=1,s=1,z. Once invitation (r = 1) and participation (s = 1) have been
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intervened on, there are no unmeasured common causes of Zr=1,s=1 and Y r=1,s=1,z because
under s = 1 the assignment mechanism is known.
In the next sections we review identifiability conditions and methods to identify the
mean outcome under joint interventions on trial engagement and treatment assignment.
Of course, identification would be straightforward if all R, S, and Z could be randomly
assigned. Random assignment of R and S, however, will be challenging, if not impossible,
in most settings. A partial exception was a randomized trial that estimated the effect of
obtaining informed consent on outcomes [22]: individuals were randomly assigned to provide
informed consent and then, regardless of their assignment, were administered a placebo. The
trial found that consent had an effect on subjective evaluation of sleep with individuals in
the no-consent group reporting “better hypnotic activity.”
In practice, identification under joint interventions on trial engagement and treatment
assignment will necessarily rely on observational data on trial invitation and participation.
As a result, the methods described in this paper will yield meaningfully interpretable esti-
mates only if sufficiently well-defined but hypothetical interventions on trial engagement can
be proposed and linked to the observed data [23].
In many cases, those hypothetical interventions may be proposed [24] and, in fact, sub-
stantive experts have explicitly discussed the conduct of hypothetical randomized trials where
invitation to participate in a trial and trial participation are randomly assigned [13, 25].
For example, Peppercorn et al. [13] noted: “Ideally, the statement that trials are the best
treatment option should rest on evidence that trial participants have better outcomes than
similar patients treated off-protocol” and described an “ethically untenable randomized trial
in which patients are randomly assigned (or not) to be offered trial participation.”
In our example, the sharing of information about obesity and strategies for weight re-
duction communicated to eligible individuals during the invitation to participate in the trial
R could be scaled-up (or investigated in a randomized trial). Similarly, any non-protocol-
mandated interventions used on trial participants S, such as counseling for smoking cessation
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or blood pressure/diabetes control, can also be scaled-up (or investigated in a randomized
trial), alongside the experimental treatment (the surgical approach Z).
Also, note that our structural description is by necessity fairly stylized. The invitation to
participate R and the participation S in the trial can be subdivided into several components.
Each of these components could be represented separately in the causal diagrams. A finer
representation of trial engagement, however, does not provide additional conceptual insights
so we chose to build our discussion around the compound treatments R and S [26].
4 Identification for joint interventions
4.1 Identifiability conditions
Because we are considering the effects of joint interventions on R, S, and Z, we need an
expanded version of the “usual” identifiability conditions of consistency, exchangeability, and
positivity [27].
Consistency conditions. We make the following consistency assumptions for every indi-
vidual i in the target population,
if Ri = 1, then Sr=1i = Si; (1)
if Ri = 1 and Si = 1, then Zr=1,s=1i = Zi; (2)
if Ri = 1, Si = 1, and Zi = z, then Y r=1,s=1,zi = Yi. (3)
These conditions connect the counterfactual variables with the corresponding observable
variables. Condition (1) means that the observed participation status among those actually
invited to participate in the trial would be the same as the counterfactual participation under
an intervention to scale-up invitation to the target population. Condition (2) means that the
observed treatment assignment among trial participants is the same as the counterfactual
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assignment under intervention to scale-up trial engagement in the entire population. Con-
dition (3) means that for trial participants who were actually assigned to treatment z, the
observed outcome is the same as the counterfactual outcome under the joint intervention on
engagement and treatment.
Condition (1) can be reasonable, provided that information about the trial can be pro-
vided in a standardized manner. Similarly, condition (2) is often reasonable, because treat-
ment assignment among trial participants is under the control of the investigators. Condition
(3), however, is somewhat stronger. It entails an assumption of no hidden versions of the
intervention [28, 29] or “treatment variation irrelevance” [30], that is to say, either there is
only one way to intervene on R, S, and Z, or the different ways of intervening have the
same effect on the outcome. This might not be true when treatments available in the actual
randomized trial are impossible to implement without substantial modification when trial
engagement is scaled-up. For example, in our motivating example of a trial comparing surgi-
cal interventions for obesity, there is some evidence that outcomes under these interventions
are better in high-volume centers [31–33]. In trials, it is not uncommon to only involve
teams from high-volume centers, but outside the confines of the trial, experience is usually
more heterogeneous. When scaling-up engagement, such heterogeneity could give rise to
outcome-relevant variation in the implementation of the interventions, violating condition
(3). It is possible to extend our results to address multiple versions of treatment along the
lines suggested in [26], provided the versions can be described and assessed (measured) in
the data (we return to this issue in the Discussion).
All three consistency conditions entail assumptions of no interference between units [34];
that is to say, that the counterfactual outcomes Sr=1, Zr=1,s=1, and Y r=1,s=1,z of each individ-
ual are not affected by the trial engagement and treatment status of any other individual.
For condition (2) this assumption appears fairly mild since it seems plausible that for the
ith individual actually participating in the trial, the observed treatment assignment is the
same as the assignment had we intervened to make them participate. The non-interference
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assumptions encoded in conditions (1) and (3), however, can be consequential in certain
contexts. For example, consider a randomized trial comparing the effects of a job training
program against no training on income. Among those in the trial, individuals assigned to
the control arm might obtain and study the materials used in the training group (say, from
friends who were assigned to that group); here, the outcome of some non-randomized work-
ers, is influenced by the treatment assignment of randomized workers and condition (3) fails.
In economics, a particular type of interference is termed a “general equilibrium effect” [35].
In the aforementioned job training trial, suppose that the intervention is scaled-up to the
entire target population; then, the overall supply of trained workers in the economy would
be increased, lessening the impact of the intervention on income.
Exchangeability conditions. For every z,
Y r=1,s=1,z⊥ R∣X, (4)
Y r=1,s=1,z⊥ Sr=1∣X,R, and (5)
Y r=1,s=1,z⊥ Zr=1,s=1∣X,R,Sr=1. (6)
We may view conditions (4) through (6) as conditions of sequential conditional exchange-
ability, or perhaps more aptly, sequential conditional generalizability. As in the case of
time-varying treatments [27], the term “sequential” highlights that the conditions allow us
to generalize, in turn, over invitation, participation, and treatment assignment, conditional
on the observed “past” at each of these action points.
Of note, conditions (5) and (6), together with conditions (1) and (2), imply that,
Y r=1,s=1,z⊥ S∣X,R = 1 and (5∗)
Y r=1,s=1,z⊥ Z ∣X,R = 1, S = 1. (6∗)
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Condition (5∗) means that the independence of the counterfactual outcomes Y r=1,s=1,z and
trial participation S need only hold among individuals invited to participate in the trial (R =
1). Condition (6∗) means that the independence of the counterfactual outcomes Y r=1,s=1,z
and treatment Z need only hold among trial participants (S = 1), allowing confounding of
the Z → Y effect in the absence of randomization. That is to say, when Y r=1,s=1,z⊥ Z ∣X,R =
1, S = 1 holds, Y r=1,s=1,a⊥ Z ∣X,R = 1, S = 0 need not hold.
Lastly, readers should bear in mind that the above exchangeability conditions hold for
causal structures beyond the one represented by the DAG of Figure 1. For instance, the
conditions hold under a new DAG that includes the edges and nodes of Figure 1 plus the
fork X ← U∗ → Y (in this new graph, U∗ is a common cause of X and Y ). This is a
general phenomenon that applies to all the causal structures considered in our paper: the
counterfactual exchangeability conditions can be viewed as defining an equivalence class of
graphs, of which we have chosen to draw only a single member, the simplest one that allows
us to focus on the generalizability issues at hand.
Positivity conditions. We also need the following positivity conditions:
Pr[R = 1∣X = x] > 0 for every x with f(x) > 0, (7)
Pr[S = 1∣X = x,R = 1] > 0 for every x with f(x,R = 1) > 0, and (8)
Pr[Z = z∣X = x,R = 1, S = 1] > 0 for every z and every x with f(x,R = 1, S = 1) > 0; (9)
where throughout we use f to generically denote densities (the relevant density in each case
should be clear from context). Informally, the positivity conditions ensure that at least some
individuals who engage in each treatment group of the trial have the covariate patterns
needed to ensure the exchangeability conditions in the target population.
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4.2 Identification under joint intervention
Under the above assumptions, we can identify the counterfactual outcome distribution under
joint intervention to set R to r = 1, S to s = 1, and Z to z:
Pr[Y r=1,s=1,z ≤ y] = E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]]. (10)
Note here that the expectation on the right-hand-side of the above equation is with respect
to the covariate distribution of the target population, that is, the population of individuals
meeting the trial eligibility criteria (see Appendix B for derivation).
The above identification result pertains to the cumulative distribution function of the
counterfactual outcomes, not just the counterfactual outcome mean. In contrast, in prior
work we have focused on the identification of just the counterfactual outcome mean [8].
We are able to obtain a stronger result here because conditions (4) through (6) encode
assumptions of exchangeability in distribution, rather than the assumptions of exchangeability
in mean invoked in our prior work.
The right-hand side of the above equation, can be re-expressed as
E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]] = E [ I(Y ≤ y,R = 1, S = 1,Z = z)
Pr[R = 1, S = 1∣X]Pr[Z = z∣X,R = 1, S = 1]] , (11)
where I(⋅) denotes the indicator function. As has been noted before (e.g., see [27]), we
can derive this result without invoking any conditions that involve counterfactuals (we only
use the positivity conditions; see Appendix B for an illustration). Thus, the identity holds
even when the causal assumptions do not hold, but, in that case, the quantities in (11)
do not have any causal interpretation. When the assumptions hold, the inverse probabil-
ity weighting re-expression provides an alternative way for identifying the counterfactual
outcome distribution.
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5 When trial engagement does not directly affect the
outcome
When we can assume that trial engagement effects are negligible, that is to say, the invitation
to participate in the trial and trial participation itself do not have a direct effect on the
outcome, the DAG of Figure 1 is modified by removing the arrows from R and S to Y ,
resulting in the DAG of Figure 3.
A randomized trial by Milkman et al. [36] provides a good example of a trial in which it is
plausible that trial participation does not have any effect on the outcome except through the
assigned treatment. Briefly, the investigators wanted to study the impact of different types
of mailed prompts on vaccination rates. Using routinely collected insurance information
they identified trial-eligible employees in a large firm and randomly assigned them to three
treatment groups, which received different prompts about vaccination. Members of the target
population were unaware of the eligibility screening process, the requirement for informed
consent was waived, there as no indication in the letters that a trial was being conducted,
and outcomes were ascertained using routinely collected data sources. As such, in this study
it is plausible that there were no direct effects of participation, that is, trial participation
affected the outcome only through treatment assignment.
Figure 4 shows the SWIG for joint intervention to set S to s = 1 and Z to z under the
DAG of Figure 3. Note that this SWIG differs from the one in Figure 2 in two ways: first,
the arrow from s = 1 into the counterfactual outcome has been removed, because the arrow
was absent in the DAG of Figure 3. Second, the counterfactual outcome is indexed only
by the intervention to set treatment Z to z, but it is no longer indexed by the intervention
to set R or S (in SWIG construction, this is referred to as minimal labeling). In effect,
the removal of the R → Y and S → Y arrows from the DAG reflects exclusion restriction
assumptions implying that Y r=1,s=1,zi = Y zi , for every individual i and every treatment z.
Under this exclusion restriction, the steps in Appendix B.1 would not be affected except to
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substitute Y zi for Y
r=1,s=1,z
i ; thus, we conclude that, under the DAG in Figure 3,
Pr[Y z ≤ y] = Pr[Y r=1,s=1,z ≤ y] = E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]].
6 Connection with censoring adjustments in time-fixed
treatment studies with short follow-up
Consider the identification of the counterfactual outcome distribution in randomized or ob-
servational studies of time-fixed treatments with longitudinal follow-up. In such studies,
individuals who enter the study are often censored (drop-out or are lost-to-follow-up) and
identification needs to account for the censoring mechanism. In Appendix C we consider a
study of a time-fixed treatment with complete adherence to assigned treatment and short
follow-up (e.g., a study of patients’ food consumption on the 30th post-operative day fol-
lowing bariatric surgery). In such a study, no outcome information will be available for
individuals who chose to not complete the study questionnaire and the analysis needs to
account for factors that are common causes of loss-to-follow-up and the outcome of interest.
A natural causal quantity of interest in such a study is the counterfactual outcome dis-
tribution under intervention to set Z to z and eliminate censoring [27]. In Appendix C, we
show that the conditions needed to identify this quantity and the identification results are
strikingly similar to those for identifying the counterfactual outcome distribution under in-
tervention to scale-up trial engagement and set Z to z. The similarity should make intuitive
sense: generalizability analyses address the issue of individuals not entering the trial because
they did not know about it or opted not to participate; censoring-adjusted analyses address
the issue of individuals prematurely exiting the trial.
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7 Time-varying treatments
Up to now, we have discussed time-fixed treatments in studies with complete adherence
and short follow-up, such that censoring can be treated as a binary variable. We used this
approach because the conceptual issues related to the generalizability of causal inferences
from randomized trials to a target population can be illuminated in this simple setting.
That said, in realistic applications of generalizability methods the treatments of interest
will usually need to be sustained over time, adherence to the assigned treatment will be
incomplete, and loss to follow-up will occur at different time points during follow-up (e.g., [37]
discuss non-adherence in the context of generalizability analyses). We can readily extend the
ideas in the previous sections to address time-varying treatments, including interventions to
promote adherence to the assigned treatment or to eliminate censoring in follow-up studies.
To illustrate this point, we expand our causal structure and introduce some more notation
to consider a two-period study, where treatment assignment Z at baseline is followed by an
initial treatment period, and where treatment may be sustained (or not) for a second period.
Let A0 denote the decision to to receive treatment (or not) during the initial treatment period
and A1 the decision to to receive treatment (or not) during the second treatment period.
As before, the outcome Y is assessed at the end of the study. Information is collected on
time-varying covariates, in addition to the baseline covariates X . Specifically, information
on time varying covariates L0 is collected after treatment assignment, at the start of the
initial treatment period (i.e., between Z and A0) and information on time varying covariates
L1 is collected after the initial treatment period, at the start of the second treatment period
(i.e., between A0 and A1). Suppose also that the time-varying covariates affect the receipt
of future treatment as well as the outcome, and thus are time-varying confounders (see
chapter 19 of [27]). Individuals may be censored at the end of the first treatment period
(i.e., before L1 is determined) or the end of the second treatment period (i.e., before Y is
determined). Let C1 be the indicator for censoring before the end of the first treatment
period and C2 the indicator for censoring before the end of the second treatment period;
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Cj = 1 if censored before the end of the jth treatment period, and 0 otherwise, for j = 1,2.
We use overbars to denote histories of random variable that are observed over time; for
example, A = (A0,A1); L = (L0,L1), and C = (C1,C2). We use corresponding lowercase
symbols to denote realizations of these histories; for example, we denote a specific treatment
history as a = (a0, a1); a censoring history as c = (c1, c2); and the intervention to eliminate
censoring as c = (0,0) ≡ 0.
Under assumptions analogous to the ones we made earlier in the paper (see Appendix
D), we can identify the distribution of counterfactual outcomes under intervention to scale-
up trial engagement, set treatment to z, enforce adherence to treatment a = (a0, a1), and
prevent censoring c = 0, Pr[Y r=1,s=1,z,a,c=0 ≤ y], using the g-formula functional or its inverse
probability weighting re-expression,
Pr[Y r=1,s=1,z,a,c=0 ≤ y]
= E[E[E [Pr[Y ≤ y∣X,R = 1, S = 1,Z = z,L,A = a,C = 0]∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[ I(Y ≤ y,R = 1, S = 1,Z = z,A = a,C = 0)
Pr[R = 1, S = 1∣X]Pr[Z = z∣X,R = 1, S = 1] × Pa ×Pc ] ,
where in the last expression above, we define
Pa = Pr[A1 = a1∣X,R = 1, S = 1,Z = z, L,A0 = a0,C1 = 0]
×Pr[A0 = a0∣X,R = 1, S = 1,Z = z,L0], and
Pc = Pr[C2 = 0∣X,R = 1, S = 1,Z = z,L,A = a,C1 = 0]
×Pr[C1 = 0∣X,R = 1, S = 1,Z = z,L0,A0 = a0].
The inverse probability weighting re-expression above will be familiar to readers who have
studied the identification of the parameters of marginal structural models for time-varying
treatments (e.g., see [38–40]).
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8 Discussion
We argue that attempts to generalize inferences from randomized trials to the population of
trial-eligible individuals require the notion of interventions to scale-up trial engagement to the
population of eligible individuals [41]. Prior work on generalizability has nearly exclusively
focused on interventions on treatment assignment Z without considering the possibility of
intervention on the invitation to participate in the trial R or trial participation S. We
are only aware of two previous papers that introduced notation for intervention on trial
participation (but not on the invitation to participate) [42, 43]. Thus, subtleties related to
the effects of trial engagement on the outcome have largely remained unappreciated.
Our approach connects with the broad literature on selective study participation [44]
and clarifies the meaning of generalizability analyses when trial engagement directly affects
the outcome. Under causal models that allow for such direct effects (e.g., Figure 1), when
only intervention on Z is contemplated, it is not true that Y z⊥ S∣X . Yet, this condition
(or close variants) has been invoked in prior work [2–8, 45, 46]. Our results suggest an
alternative interpretation for this prior work: in the presence of trial engagement effects,
generalizability analyses cannot identify the effect of intervening to just set treatment to a
particular level in the target population; but, they can identify the effect of jointly intervening
to scale-up the outcome-relevant trial procedures to the entire target population and set
treatment. When engagement effects are negligible, generalizability analyses can identify
the effect of interventions to set treatment, regardless of whether they occur in the context
of an experimental study. Whether trial engagement effects exist or not, to generalize causal
inferences from a randomized trial to the target population of all trial-eligible individuals,
investigators need to obtain covariate data from a representative sample of that population.
Because we wanted to focus on general concepts of generalizability, our exposition was
fairly stylized. In particular, we did not spend much time on the policy-relevant work
of carefully specifying which components of invitation R and participation S are actually
responsible for direct effects on the outcome. Such work will be necessary when scaling-up
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randomized trials in practice. For example, policy-makers need to consider what information
should be provided to individuals eligible for treatment and by what means (accounting for
R effects) or whether non-protocol-mandated provider behaviors observed in the trial should
also be implemented in the the target population (accounting for S effects).
Bareinboim and Pearl have proposed general methods to assess identifiability and, when
possible, to identify the post-intervention distribution in a target population by “transport-
ing” information from other sources [47–49]. The methods rely on DAGs enhanced with
selection nodes, but do not address issues related to trial engagement effects because they
do not represent interventions on the selection nodes. We chose to focus on the concrete
problem of generalizing inferences using trials nested within cohorts of eligible individuals
because such studies will be increasingly conducted by embedding pragmatic randomized
trials in large health-care systems [50–52]. We did not, however, address the somewhat more
ambitious goal of extending trial findings to populations ineligible for the trial.
The extension of our results to handle non-adherence and time-varying treatments illus-
trates that generalizability analyses, which address selective study participation, fit naturally
within the “usual” causal inference framework in epidemiology and the social sciences: first,
select the causal quantities of interest that are well-defined in the target population. Then,
determine the identifiability conditions needed in the presence of selective trial participation,
confounding, censoring, or non-adherence as assumptions about a sequence of interventions
to “scale-up” the trial, set treatment, eliminate censoring, and enforce adherence. Next,
using these assumptions, find the functionals of the observed data distribution that identify
the causal quantities of interest. Last, and not addressed in our paper, estimate the observed
data functionals using appropriate statistical methods [39, 53, 54].
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10 Figures
Figure 1: DAG depicting the invitation to participate, participation, and treatment assign-
ment in a randomized trial.
X
(A)
R S Z Y
U
X
(B)
R=1 S=1 Z Y
U
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Figure 2: SWIG for joint intervention on R, S, and Z.
X R ∣ r=1 Sr=1 ∣ s=1 Zr=1,s=1 ∣ z Y r=1,s=1,z
20
Figure 3: DAG for a trial nested in a cohort study, when trial participation does not affect
outcomes.
X R S Z Y
Figure 4: SWIG for joint intervention on S and Z, in the absence of trial engagement effects.
X R ∣ r=1 Sr=1 ∣ s=1 Zr=1,s=1 ∣ z Y z
21
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Appendix A Brief overview of Single World Interven-
tion Graphs (SWIGS)
Starting with a causal DAG about the factual (i.e., observable, even if unmeasured) variables,
a SWIG [16,17] is obtained by positing interventions on certain nodes; we refer to these nodes
as “intervention nodes.”
First, we “split” intervention nodes into a “random part” that can be thought as repre-
senting the (random) variable in the absence of intervention; and a “fixed part” representing
the specific intervention under consideration. In this paper, we use a vertical line to denote
node splitting. For example, intervention to set Z to z = 1 would be depicted as Z ∣ z = 1.
Next, for each split note, incoming arrows on the DAG point into the random part on the
SWIG; outgoing arrows on the DAG emanate from the fixed part on the SWIG; otherwise,
arrows are left unchanged.
All descendants of intervention nodes are then relabeled to depict the corresponding
counterfactual random variables under the specific intervention under consideration; this
is done to signify that, for the descendants of intervention nodes, only post-intervention
measurements are possible in the “world” where we have intervened in our chosen way.
Nodes representing random variables can be treated as belonging to a “conventional”
DAG – that is to say, the usual rules of d-separation [18, 19] can be used to read-off inde-
pendence conditions from SWIGs, with the additional property that the fixed nodes block
the paths they are intercepting.
A note on terminology: Strictly speaking, graphs like the one in Figure 2 are “single
world intervention templates” (SWITs) because by substituting different specific values for
z we can use the graph to represent SWIGs under different interventions (formally, a SWIT
is a graph-valued function). Because there is no possibility of confusion here, we informally
refer to graphs like Figure 2 as SWIGs.
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Appendix B Intervention to scale-up trial engagement
and set treatment
B.1 Identification via g-formula computation
Pr[Y r=1,s=1,z ≤ y] = E[Pr[Y r=1,s=1,z ≤ y∣X]]
= E[Pr[Y r=1,s=1,z ≤ y∣X,R = 1]]
= E[Pr[Y r=1,s=1,z ≤ y∣X,R = 1, S = 1]]
= E[Pr[Y s=1,z ≤ y∣X,R = 1, S = 1,Z = z]]
= E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]],
where the first equality follows from the law of total expectation; the second from condition
(4); the third from condition (5∗); the fourth from condition (6∗); and the last from conditions
(1) through (3). Expressions are well defined because of conditions (7) through (9).
B.2 Identification via inverse probability weighting
We can derive the identity in (11) as follows:
E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]] = E[Pr[Y ≤ y∣X,S = 1,Z = z]Pr[R = 1, S = 1,Z = z∣X]
Pr[R = 1, S = 1,Z = z∣X] ]
= E
⎡⎢⎢⎢⎢⎣
E [ I(Y ≤ y,R = 1, S = 1,Z = z)
Pr[R = 1, S = 1∣X]Pr[Z = z∣X,R = 1, S = 1]∣X]
⎤⎥⎥⎥⎥⎦
= E[ I(Y ≤ y,R = 1, S = 1,Z = z)
Pr[R = 1, S = 1∣X]Pr[Z = z∣X,R = 1, S = 1]] ,
where I(⋅) denotes the indicator function.
Note that in the above derivation did not use any conditions that involve counterfactual
outcomes; thus, the result holds even if E[Pr[Y ≤ y∣X,R = 1, S = 1,Z = z]] does not have a
causal interpretation.
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Appendix C Relationship with identification results in
studies with short term follow-up and post-treatment
assignment dropout
In randomized or observational studies with longitudinal follow-up, individuals who enter the
study often drop-out or are lost-to-follow-up. Let C be an indicator for prematurely exiting
the study (1 if the individual is censored and 0 if the individual completes the study). A
DAG representing the assumption that censoring may be dependent on baseline covariates
and treatment is depicted in Figure C1; note that the DAG also makes the conventional (see
Chapter 8 of [27]) assumption that censoring does not have a direct effect on the outcome
(absence of C → Y arrow). We have placed a box around the C node to denote that the
analysis has to be restricted to individuals who were not censored, because no outcome data
is available from censored individuals. The rest of the notation is the same as in previous
sections, except that we omit the S node to focus on censoring.
In Figure C2 we show the SWIG generated from Figure C1 for a hypothetical intervention
setting treatment Z to z and to eliminate censoring by setting C to c = 0. We use the
exclusion restriction of no C-on-Y effect in the DAG, which means that the counterfactual
outcomes in the SWIG need only be indexed by z but not c = 0 (another application of
minimal labeling).
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Figure C1: DAG for censoring in a cohort study.
X Z C Y
Figure C2: SWIG for joint intervention on Z and C.
X Z ∣ z Cz ∣ c=0 Y z
We use the following consistency conditions:
if Zi = z, then Czi = Ci; and
if Zi = z and C = 0, then Y z,c=0i = Yi.
Furthermore, by the exclusion restriction of no C-on-Y effect, we have that Y z,c=0i = Y zi , and
we can read-off the following independence conditions from the SWIG of Figure C2:
Y z⊥ Z ∣X and Y z⊥ Cz ∣X,Z.
Using consistency, the second condition can be written as Y⊥ C ∣X,Z = z.
Lastly, we use the following positivity conditions, for every z,
Pr[Z = z∣X = x] > 0, for every f(x) > 0; and
Pr[C = 0∣X = x,Z = z] > 0, for every x such that f(x,Z = z) > 0.
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C.1 Identification via g-formula computation
Pr[Y z,c=0 ≤ y] = E[Pr[Y z,c=0 ≤ y∣X]]
= E[Pr[Y z,c=0 ≤ y∣X,Z = z]]
= E[Pr[Y z,c=0 ≤ y∣X,Z = z,C = 0, ]]
= E[Pr[Y ≤ y∣X,Z = z,C = 0]],
where all steps follow from the identifiability conditions above.
C.2 Identification via inverse probability weighting
We now show how identification is possible via inverse probability weighting:
E[Pr[Y ≤ y∣X,Z = z,C = 0]] = E[Pr[Y ≤ y∣X,Z = z,C = 0]Pr[Z = z∣X]Pr[C = 0∣X,Z = z]
Pr[Z = z∣X]Pr[C = 0∣X,Z = z] ]
= E[ E[I(Y ≤ y,Z = z,C = 0)∣X]
Pr[Z = z∣X]Pr[C = 0∣X,Z = z]]
= E
⎡⎢⎢⎢⎢⎣
E [ I(Y ≤ y,Z = z,C = 0)
Pr[Z = z∣X]Pr[C = 0∣X,Z = z] ∣X]
⎤⎥⎥⎥⎥⎦
= E [ I(Y ≤ y,Z = z,C = 0)
Pr[Z = z∣X]Pr[C = 0∣X,Z = z]] .
Again, the above derivation does not invoke any assumptions that involve counterfactual
outcomes; thus, the result holds even when E[Pr[Y ≤ y∣X,Z = z,C = 0]] does not have a
causal interpretation.
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Appendix D Time-varying treatments
D.1 Causal quantities of interest and identifiability conditions
We wish to identify Pr[Y r=1,s=1,z,a,c=0 ≤ y], the counterfactual outcome distribution under
intervention to scale-up trial engagement (r = 1, s = 1), assign treatment z, enforce adherence
a = (a0, a1), and prevent censoring c = 0.
Now, suppose that we are willing to make a series of consistency, exchangeability, and
positivity conditions that are “natural” generalizations of the conditions we used for time-
fixed treatments [38–40, 53].
Consistency conditions. For every individual i in the target population, and every z, a0,
and a1:
if Ri = 1, then Sr=1i = Si;
if Ri = 1 and Si = 1, then Zr=1,s=1i = Zi;
if Ri = 1, Si = 1, and Zi = z, then Lr=1,s=1,z0i = L0i;
if Ri = 1, Si = 1, and Zi = z, then Ar=1,s=1,z0i = A0i;
if Ri = 1, Si = 1,Zi = z, and A0i = a0, then Cr=1,s=1,z,a01i = C1i;
if Ri = 1, Si = 1,Zi = z,A0i = a0,C1i = 0, then Lr=1,s=1,z,a0,c1=01i = L1i;
if Ri = 1, Si = 1,Zi = z,A0i = a0,C1i = 0, then Ar=1,s=1,z,a0,c1=01i = A1i;
if Ri = 1, Si = 1,Zi = z,A = a, and C1i = 0, then Cr=1,s=1,z,a,c1=02i = C2i; and
if Ri = 1, Si = 1,Zi = z,A = a, and C = 0, then Y r=1,s=1,z,a,c=0i = Yi.
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Exchangeability conditions. Under intervention to scale-up trial engagement r = 1, s = 1,
assign treatment z, enforce adherence to treatment a = (a0, a1), and prevent censoring c = 0
(graph not shown), for every z, a = (a0, a1), c = (c1, c2), suppose the following conditions
hold:
Y r=1,s=1,z,a,c=0⊥R∣X ;
Y r=1,s=1,z,a,c=0⊥ Sr=1∣X,R;
Y r=1,s=1,z,a,c=0⊥ Zr=1,s=1∣X,R,Sr=1;
Y r=1,s=1,z,a,c=0⊥A
r=1,s=1,z
0 ∣X,R,Sr=1,Zr=1,s=1,Lr=1,s=1,z0 ;
Y r=1,s=1,z,a,c=0⊥C
r=1,s=1,z,a0
1 ∣X,R,Sr=1,Zr=1,s=1,Lr=1,s=1,z0 ,Ar=1,s=1,z0 ;
Y r=1,s=1,z,a,c=0⊥A
r=1,s=1,z,a0,c1=0
1 ∣X,R,Sr=1,Zr=1,s=1,Lr=1,s=1,z0 ,Ar=1,s=1,z0 ,Cr=1,s=1,z,a01 ,Lr=1,s=1,z,a0,c1=01 ; and
Y r=1,s=1,z,a,c=0⊥C
r=1,s=1,z,a,c1=0
2 ∣X,R,Sr=1,Zr=1,s=1,Lr=1,s=1,z0 ,Ar=1,s=1,z0 ,Cr=1,s=1,z,a01 ,Lr=1,s=1,z,a0,c1=01 ,Ar=1,s=1,z,a0,c1=01 .
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Note that, when combined with the consistency conditions, the above exchangeability
conditions imply
Y r=1,s=1,z,a,c=0⊥ R∣X ;
Y r=1,s=1,z,a,c=0⊥ S∣X,R = 1;
Y r=1,s=1,z,a,c=0⊥ Z ∣X,R = 1, S = 1;
Y r=1,s=1,z,a,c=0⊥ A0∣X,R = 1, S = 1,Z = z,L0;
Y r=1,s=1,z,a,c=0⊥ C1∣X,R = 1, S = 1,Z = z,L0,A0 = a0;
Y r=1,s=1,z,a,c=0⊥ A1∣X,R = 1, S = 1,Z = z,L,A0 = a0,C1 = 0; and
Y r=1,s=1,z,a,c=0⊥ C2∣X,R = 1, S = 1,Z = z, L,A = a,C1 = 0.
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Positivity conditions. We also need the following positivity conditions, for every z and
every a,
Pr[R = 1∣X = x] > 0, for every x with f(x) > 0;
Pr[S = 1∣X = x,R = 1] > 0, for every x with f(x,R = 1) > 0;
Pr[Z = z∣X = x,R = 1, S = 1] > 0, for every x with f(x,R = 1, S = 1) > 0;
Pr[A0 = a0∣X = x,R = 1, S = 1,Z = z,L0 = l0] > 0,
for every x, l0 with f(x, l0,R = 1, S = 1,Z = z) > 0;
Pr[C1 = 0∣X = x,R = 1, S = 1,Z = z,L0 = l0,A0 = a0] > 0,
for every x, l0 with f(x, l0,R = 1, S = 1,Z = z,A0 = a0) > 0;
Pr[A1 = a1∣X = x,R = 1, S = 1,Z = z, L = l,A0 = a0,C1 = 0] > 0,
for every x, l with f(x, l,R = 1, S = 1,Z = z,A0 = a0,C1 = 0) > 0; and
Pr[C2 = 0∣X = x,R = 1, S = 1,Z = z,L = l,A = a,C1 = 0] > 0,
for every x, l with f(x, l,R = 1, S = 1,Z = z,A = a,C1 = 0) > 0.
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D.2 Identification
Pr[Y r=1,s=1,z,a,c=0 ≤ y]
= E[Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X]]
= E[Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1]]
= E[Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1]]
= E[Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z]]
= E[E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z,L0]∣X,R = 1, S = 1,Z = z]]
= E[E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z,L0,A0 = a0]∣X,R = 1, S = 1,Z = z]]
= E[E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[E [E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z, L,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[E [E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z, L,A = a,C1 = 0]∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[E [E [Pr[Y r=1,s=1,z,a,c=0 ≤ y∣X,R = 1, S = 1,Z = z, L,A = a,C = 0]∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[E[E [Pr[Y ≤ y∣X,R = 1, S = 1,Z = z,L,A = a,C = 0]∣X,R = 1, S = 1,Z = z,L0,A0 = a0,C1 = 0]∣X,R = 1, S = 1,Z = z]]
= E[ I(Y ≤ y,R = 1, S = 1,Z = z,A = a,C = 0)
Pr[C2 = 0,A1 = a1∣X,R = 1, S = 1,Z = z,L,A0 = a0,C1 = 0]Pr[C1 = 0,A0 = a0∣X,R = 1, S = 1,Z = z,L0]Pr[R = 1, S = 1,Z = z∣X]]
= E[ I(Y ≤ y,R = 1, S = 1,Z = z,A = a,C = 0)
Pr[R = 1, S = 1∣X]Pr[Z = z∣X,R = 1, S = 1] × Pa ×Pc ] ,
where in the last expression above, we define
Pa = Pr[A1 = a1∣X,R = 1, S = 1,Z = z, L,A0 = a0,C1 = 0]
×Pr[A0 = a0∣X,R = 1, S = 1,Z = z,L0], and
Pc = Pr[C2 = 0∣X,R = 1, S = 1,Z = z,L,A = a,C1 = 0]
×Pr[C1 = 0∣X,R = 1, S = 1,Z = z,L0,A0 = a0].
Extensions to multiple time-points, which would be necessary to capture more complex
patterns of non-adherence over time, are well-known [38–40, 53] and do not alter any of our
conclusions regarding generalizability to a target population.
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